Swedish Orphan Biovitrum AB, the Solna, Sweden-based speciality pharma company, is ramping up its immunology focus to build a second significant pillar alongside its hemophilia franchise. Adding to its growing Kineret (anakinra) business and the November 2018 acquisition of US rights to commercialize Synagis (palivizumab) from AstraZeneca PLC, Sobi has now exercised its option to acquire Gamifant (emapalumab) from Novimmune SA (Also see "Novimmune Sells Gamifant And IO Assets To Sobi" - Scrip, 14 June, 2019.)(Also see "Sobi Advances Growth Strategy With Gamifant Launch In Early 2019 For Primary HLH" - Scrip, 21 November, 2018.), as well as employees involved in the clinical and biopharmaceutical development of the program. The consideration is CHF515m ($519m), of which CHF400m had already been committed in the license agreement.
Sobi Realigns Focus On Late-Stage Hematology & Immunology Assets
Swedish specialty pharma and rare diseases company seeks to sustain recent rapid revenues growth with increased R&D focus and investments in its hematology and immunology franchises.
More from Immunological
The biotech is banking on itolizumab’s longer-term efficacy as well as unmet need in frontline acute graft-versus-host disease as it prepares to meet with the FDA.
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
Obefazimod has been heralded as a potential blockbuster for ulcerative colitis and there will be great interest in the readout of Phase III induction trials in the third quarter of this year.
The development could highlight the power of competitive market forces over government price controls or suggest Medicare price negotiation is enhancing competitive market forces.
More from Therapy Areas
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.